Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Clearmind Medicine Inc. (Nasdaq:...
-
Lilly taps Juvena's AI platform, the first to map the therapeutic potential of secreted proteins, to discover treatments that improve muscle health.
-
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma...
-
60 Degrees launches 8-count ARAKODA® bottles, offering weekly malaria protection for short trips. Now available via major retail pharmacies.
-
Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.
-
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
-
60 Degrees Pharma reports Q1 2025 revenue up 55% to $163.6K, gross profit up 124%, driven by Arakoda sales.
-
MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and...
-
MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results...
-
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting...